RxDoctor Payments Data

Ben Harvey, MD

Glaucoma Specialist · Oklahoma City, OKNPI 1447448907

Payments from drug & device makers

$43,014in general payments, 2019–2025

Across 189 payments — averaging $227.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$23K
  • AbbVie$13K
  • Alcon$6K
  • The Cameron-ehlen Group, Inc.$302
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$101
  • Sight Sciences, Inc.$97
  • plus $431 from 11 others
$10in research payments, 2019–2025

Across 1 payment — averaging $10.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$10

What the payments were for

  • Consulting fees$1,9806%
  • Speaking & faculty fees$28,04978%
  • Travel & lodging$5331%
  • Food & beverage$5,15714%
  • Gifts$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$408,019
Medicare patients
852
Services billed
3,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate334$121,491
CombiganBrimonidine Tartrate/Timolol76$29,205
LumiganBimatoprost48$26,227
SimbrinzaBrinzolamide/Brimonidine Tart55$12,479
Latanoprost1,095$11,378
VyzultaLatanoprostene Bunod25$11,160
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol38$8,685
Alphagan PBrimonidine Tartrate25$8,680
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat565$8,128
RocklatanNetarsudil Mesylat/Latanoprost17$6,356
Brimonidine Tartrate503$6,130
Travoprost39$5,266
Prednisolone Acetate121$5,243
Brinzolamide20$4,680
Dorzolamide Hcl211$4,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$23,436$127,847351 claims
AbbVieCombigan, Lumigan, Alphagan P$12,807$64,112149 claims
AlconSimbrinza$5,840$12,47955 claims
Bausch & Lomb Americas Inc.Vyzulta$29$11,16025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Oklahoma City

Where these figures come from

Is this you, or does something look wrong? →